Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Gross Margin: 2011-2025

Historic Gross Margin for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to 56.34%.

  • Adma Biologics' Gross Margin rose 656.00% to 56.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.71%, marking a year-over-year increase of 578.00%. This contributed to the annual value of 51.48% for FY2024, which is 1704.00% up from last year.
  • Latest data reveals that Adma Biologics reported Gross Margin of 56.34% as of Q3 2025, which was up 2.24% from 55.11% recorded in Q2 2025.
  • Adma Biologics' Gross Margin's 5-year high stood at 56.34% during Q3 2025, with a 5-year trough of -10.73% in Q1 2021.
  • Moreover, its 3-year median value for Gross Margin was 49.78% (2024), whereas its average is 44.63%.
  • The largest annual percentage gain for Adma Biologics' Gross Margin in the last 5 years was 32,695bps (2021), contrasted with its biggest fall of 9,435bps (2021).
  • Adma Biologics' Gross Margin (Quarterly) stood at 6.38% in 2021, then soared by 2,198bps to 28.36% in 2022, then skyrocketed by 1,370bps to 42.06% in 2023, then surged by 1,182bps to 53.88% in 2024, then surged by 656bps to 56.34% in 2025.
  • Its Gross Margin stands at 56.34% for Q3 2025, versus 55.11% for Q2 2025 and 53.22% for Q1 2025.